Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019

Hong, Seri; Kang, Mee Joo; Kim, Taegyu; Jung, Kyu‐Won; Kim, Bong-Wan

doi:10.14701/ahbps.22-044

Cited by 10 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to recent studies examining the trends in liver cancer in Korea over the past 20 years, it is evident that increased early detection of hepatocellular carcinoma has led to an improvement in the 5-year survival rate among patients undergoing surgical treatment [9][10][11]. Surgeons utilize numerous techniques to reduce blood loss during partial liver resection.…”

Section: Discussionmentioning

confidence: 99%

A Prospective Analysis of the Effects of a Powder-Type Hemostatic Agent on the Short-Term Outcomes after Liver Resection

Kang,

Cho,

Han

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Postoperative bleeding is a significant cause of morbidity and mortality following liver resection. Therefore, it is crucial to minimize bleeding during liver resection and effectively manage it when it occurs. Arista® AH (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) is a microporous polysaccharide hemosphere (MPH), a new plant-derived polysaccharide powder hemostat that can be applied to the entire surgical field. This study prospectively assessed the effectiveness of Arista for bleeding control when applied intraoperatively to the liver resection surface. Materials and Methods: Data were collected at Seoul National University Bundang Hospital for patients who underwent liver resection owing to malignant hepatocellular carcinoma or benign liver diseases. We compared the outcomes between 45 patients managed with Arista® AH (data were prospectively collected between September 2022 and May 2023) and 156 patients managed without the use of Arista® AH (data were retrospectively collected between January 2021 and December 2021). Results: There were no significant differences in patient characteristics between the two groups. The estimated blood loss (EBL) was significantly lower in the Arista® AH group compared with the control group (495.56 ± 672.7 mL vs. 691.9 ± 777.5 mL, p = 0.049). The mean postoperative hospital stay was significantly shorter in the Arista® AH group (5.93 ± 1.88 days vs. 6.94 ± 4.17 days, p = 0.024). The time to Jackson-Pratt drain removal was also significantly shorter in the Arista® AH group (4.64 ± 1.31 days vs. 5.30 ± 2.87 days, p = 0.030). The patient subgroup was divided into four categories based on the type of resection and the presence or absence of cirrhosis. Within the subgroup of major resections in non-cirrhotic patients, the Arista® AH group demonstrated significantly better outcomes compared to the control group, showed lower EBL, reduced need for blood transfusions, decreased volume of drain fluid collected within 48 h, earlier removal of drains, and shorter hospital stays. In contrast, for the other subgroups such as minor resection (both non-cirrhotic and cirrhotic) and major resection with cirrhosis, the differences between the Arista® AH and control groups in various parameters like EBL, blood transfusion rates, drain fluid volume, time to drain removal, and duration of hospital stay were not statistically significant. Conclusions: Arista® AH significantly improved intraoperative blood management and postoperative recovery in patients undergoing liver resection, particularly in non-cirrhotic patients who underwent major resection.

show abstract

Section: Discussionmentioning

confidence: 99%

A Prospective Analysis of the Effects of a Powder-Type Hemostatic Agent on the Short-Term Outcomes after Liver Resection

Kang,

Cho,

Han

et al. 2024

Medicina

View full text Add to dashboard Cite

show abstract

“…Initial treatment within 4 months of diagnosis was categorized as surgical (surgery alone, surgery with chemotherapy, surgery with radiotherapy, or surgery with chemotherapy and radiotherapy), non‐surgical (chemotherapy alone, radiotherapy alone, or chemotherapy and radiotherapy), and no active treatment information. Transcatheter arterial chemoembolization was included into the non‐surgical group 40,41 …”

Section: Methodsmentioning

confidence: 99%

“…Transcatheter arterial chemoembolization was included into the nonsurgical group. 40,41 Furthermore, given prior research that reported the predictive utility of the FIB-4 score for non-HCC cancers, [42][43][44] we also conducted further investigations to assess the ability of the FIB-4 in predicting breast cancer and colorectal cancer.…”

Section: Identification Of Hcc and Non-hcc Cancer Casesmentioning

confidence: 99%

Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study

Shin,

Sohn,

Chang

et al. 2024

Hepatology Research

View full text Add to dashboard Cite

AimHepatocellular carcinoma (HCC) is a major cause of cancer‐related death, with low survival rates worldwide. Fatty liver disease (FLD) significantly contributes to HCC. We studied the screening performance of different methods for identifying HCC in patients with FLD or with metabolic risk factors for FLD.MethodsKorean adults (n=340,825) without a prior HCC diagnosis were categorized into four groups: normal (G1), ≥2 metabolic risk factors (G2), FLD (G3), and viral liver disease or liver cirrhosis (G4). The National Cancer Registry data were used to identify HCC cases within 12 months. We assessed the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, and positive and negative predictive values of individual or combined screening methods.ResultsIn 93 HCC cases, 71 were identified in G4, while 20 cases (21.5%) in G2 and G3 combined where ultrasound and fibrosis‐4 performed similarly to alpha‐fetoprotein and ultrasound. In G2, fibrosis‐4 and ultrasound had the highest AUROC (0.93 [0.87–0.99]), whereas in G3, the combined screening methods had the highest AUROC (0.98 [0.95–1.00]). The positive predictive value was lower in G2 and G3 than in G4 but was >5% when restricted to a high fibrosis‐4 score.ConclusionsMore than 21% of HCC cases were observed in patients with diagnosed FLD or at risk of FLD with metabolic risk factors. Nevertheless, screening for HCC in individuals without cirrhosis or viral hepatitis yielded very low results, despite the potential value of the fibrosis‐4 score in identifying individuals at high risk of HCC.This article is protected by copyright. All rights reserved.

show abstract

“…The overall survival (OS) of patients with primary liver cancer is gradually improving [ 5 ]. However, the incidence of liver cancer is steadily increasing [ 6 , 7 ]. More centers are accepting LLR for primary liver cancer, following the first consensus meeting, which suggested that only tumors located in the anterolateral segments can be safely resected [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Achieving Textbook Outcomes after Laparoscopic Resection in Posterosuperior Segments of the Liver: The Impact of the Learning Curve

D’Silva,

Cho,

Han

et al. 2024

Cancers

View full text Add to dashboard Cite

Achieving textbook outcomes (TOs) improves the short-term and long-term performance of a hospital. Our objective was to assess TOs in the laparoscopic liver resection (LLR) of tumors in the PS (posterosuperior) section of the liver and identify the impact of the learning curve. We conducted a retrospective cohort study analyzing patients who underwent LLR for lesions located in the PS segments. Patients were divided into a TO and no-TO group. TOs were defined as negative margins, no transfusion, no readmission, no major complications, no 30-day mortality, and a length of stay ≤ 50th percentile. Patients’ outcomes were assessed in two study periods before and after 2015. TOs were achieved in 47.6% (n = 117). In multivariable analysis, obesity (p = 0.001), shorter operation time (p < 0.001), less blood loss (p < 0.001), normal albumin (p = 0.003), and minor resection (p = 0.046) were significantly associated with achieving TOs. Although the 5-year recurrence-free survival rate (p = 0.096) was not significantly different, the 5-year overall survival rate was significantly greater in the TO group (p = 0.001). Body mass index > 25 kg/m2 (p = 0.020), age > 65 years (p = 0.049), and achievement of TOs (p = 0.024) were independently associated with survival. The proportion of patients who achieved a TO was higher after 2015 than before 2015 (52.3% vs. 36.1%; p = 0.022). TOs are important markers not only for assessing hospital and surgeon performance but also as predictors of overall survival. As the number of surgeons who achieve the learning curve increases, the number of patients with TOs will gradually increase with a subsequent improvement in overall survival.

show abstract

Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999-2019

Cited by 10 publications

References 18 publications

A Prospective Analysis of the Effects of a Powder-Type Hemostatic Agent on the Short-Term Outcomes after Liver Resection

A Prospective Analysis of the Effects of a Powder-Type Hemostatic Agent on the Short-Term Outcomes after Liver Resection

Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study

Achieving Textbook Outcomes after Laparoscopic Resection in Posterosuperior Segments of the Liver: The Impact of the Learning Curve

Contact Info

Product

Resources

About